Additionally, a second interim analysis of ORIENT-31 [12] revealed that NSCLC patients with Thr790Met-negative or EGFR exon 21 Leu858Arg mutation were more likely to benefit from combined immunotherapy than those with a Thr790Met-positive or EGFR exon 19 deletion. Here, EGFR is linked to non-small cell lung carcinoma.